loader
Please Wait
Applying Filters...

Seqens Seqens

X

List of Active Pharmaceutical Ingredients (APIs) supplied/manufactured by Cayman Pharma S.r.o

Client Virtual Booth
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 Alprostadil (1)

02 Bimatoprost (1)

03 Cloprostenol Sodium (1)

04 Epoprostenol Sodium (1)

05 Latanoprost (1)

06 Latanoprostene Bunod (1)

07 Tafluprost (1)

08 Travoprost (1)

filter

01 Cayman Pharma s.r.o (8)

filter

01 Czech Republic (8)

Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from ...
Cayman Pharma, a leading European provider of cGMP prostaglandin APIs, was formed in 2006 through the merger of Cayman Chemical and NeraPharm, both with vast expertise in prostaglandin chemistry. With almost 60 years of experience, Cayman Pharma owns and uses a patented route for the prostaglandin core structure and has received GMP approvals from European and US regulatory agencies. The company offers validated GMP routes and regulatory approvals for various therapeutic areas, including fertility, eye care, glaucoma and pulmonary hypertension, enabling the development and market launch of its products.
Post Enquiry
POST ENQUIRY